Home>
US Stocks>
Vertex Pharmaceuticals

Vertex Pharmaceuticals share price today

(VRTX)

Vertex Pharmaceuticals share price is $407.2 & ₹34,676.74 as on 25 Dec 2024, 2.30 'hrs' IST

$407.2

▲

1.93

(0.48%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Vertex Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Vertex Pharmaceuticals from India. Also see the sentimental analysis on Indian investors investing in Vertex Pharmaceuticals. Get details on the Indian mutual funds that are investing in Vertex Pharmaceuticals. Get Analyst recommendations and forecasts along with all the Vertex Pharmaceuticals's financials.

Vertex Pharmaceuticals share price movements

Today's Low: $402.32
Today's High: $410.68
$407.20
1.2%
Downside
Day's Volatility :2.04%
Upside
0.85%
52 Weeks Low: $377.85
52 Weeks High: $519.88
$407.20
7.21%
Downside
52 Weeks Volatility :27.32%
Upside
21.67%

Vertex Pharmaceuticals Returns

Period	Vertex Pharmaceuticals Incorporated	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	-12.23%	-10.0%	9.4%
6 Months	-14.5%	-5.7%	13.0%
1 Year	-0.59%	2.8%	31.8%
3 Years	82.27%	-0.4%	26.3%

Vertex Pharmaceuticals Key Statistics

in dollars & INR

Previous Close	$405.27
Open	$401.53
Today's High	$410.68
Today's Low	$402.3188
Market Capitalization	$102.3B
Today's Volume	$2.2M
52 Week High	$519.88
52 Week Low	$377.85
Revenue TTM	$10.6B
EBITDA	$4.4B
Earnings Per Share (EPS)	$-1.91
Profit Margin	-4.51%
Quarterly Earnings Growth YOY	0.01%
Return On Equity TTM	-2.98%

How to invest in Vertex Pharmaceuticals from India?

It is very easy for Indian residents to invest directly in Vertex Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Vertex Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Vertex Pharmaceuticals or VRTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Vertex Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Vertex Pharmaceuticals shares which would translate to 0.002 fractional shares of Vertex Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Vertex Pharmaceuticals, in just a few clicks!

Returns in Vertex Pharmaceuticals for Indian investors in Rupees

Investment Value

₹1,00,000

Vertex Pharmaceuticals investment value today

Current value as on today

₹1,02,286

Returns

₹2,286

(+2.29%)

Returns from Vertex Pharmaceuticals Stock

₹113 (-0.11%)

Dollar Returns

₹2,399 (+2.4%)

Indian investors sentiment towards Vertex Pharmaceuticals

13.33%

Period: Sep 25, 2024 to Dec 24, 2024. Change in 30 Days versus previous period

Investment in Vertex Pharmaceuticals from India has grown in the last 30 days as on Dec 25, 2024. 13.33% more purchase transactions for Vertex Pharmaceuticals in the last 30 days versus the previous period.

37%

Period: Sep 25, 2024 to Dec 24, 2024. Change in 30 Days versus previous period

Search volume for Vertex Pharmaceuticals on INDmoney from India has grown in the last 30 days as on Dec 25, 2024. 37% more investors are searching Vertex Pharmaceuticals in the last 30 days versus the previous period.

Indian Mutual Funds that invest in Vertex Pharmaceuticals

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	2218	-42.41	0.23%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	361	0.00	0.92%
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	3344	0.00	0.81%

Global Institutional Holdings in Vertex Pharmaceuticals

Capital World Investors
10.41%
Vanguard Group Inc
8.99%
BlackRock Inc
8.28%
State Street Corp
4.59%
FMR Inc
4.09%
Capital Research Global Investors
3.50%

Analyst Recommendation on Vertex Pharmaceuticals

Buy

68%Buy

26%Hold

5%Sell

Based on 38 Wall street analysts offering stock ratings for Vertex Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 38 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Vertex Pharmaceuticals

What analysts predicted

Upside of 22.39%

Current:

$407.20

Target:

$498.37

Insights on Vertex Pharmaceuticals

Price Movement
In the last 7 days, VRTX stock has moved down by -13.6%
Increasing Revenue
Vertex Pharmaceuticals Incorporated has shown positive revenue growth over the last two quarters, increasing from $2.63 billion to $2.77 billion. This reflects an average increase of 5.0% per quarter.
Increasing Net Profit
Vertex Pharmaceuticals Incorporated has seen a significant improvement in its profit over the last two quarters. The net profit increased from a loss of $3.59 billion to a profit of $1.04 billion. This represents an average increase of 443.8% per quarter, indicating a strong upward trend in the company's financial performance.
VRTX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 26.8% return, outperforming this stock by 26.8%
Price to Sales
Vertex Pharmaceuticals Incorporated has a Price-to-Sales (P/S) ratio of 9.8, meaning that for every $1 of sales the company generates, investors are willing to pay $9.80. In comparison, investors are willing to pay $14.70 for every $1 of sales generated by Alnylam Pharmaceuticals, indicating that Vertex is valued lower relative to its sales than Alnylam.

Vertex Pharmaceuticals Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$3.0B	↑ 22.46%
Net Income	$2.1B	↑ 695.83%
Net Profit Margin	68.8%	↑ 58.21%

	FY19	Y/Y Change
Revenue	$4.2B	↑ 36.59%
Net Income	$1.2B	↓ 43.88%
Net Profit Margin	28.27%	↓ 40.53%

	FY20	Y/Y Change
Revenue	$6.2B	↑ 49.07%
Net Income	$2.7B	↑ 130.43%
Net Profit Margin	43.7%	↑ 15.43%

	FY21	Y/Y Change
Revenue	$7.6B	↑ 22.06%
Net Income	$2.3B	↓ 13.63%
Net Profit Margin	30.92%	↓ 12.78%

	FY22	Y/Y Change
Revenue	$8.9B	↑ 17.91%
Net Income	$3.3B	↑ 41.84%
Net Profit Margin	37.2%	↑ 6.28%

	FY23	Y/Y Change
Revenue	$9.9B	↑ 10.51%
Net Income	$3.6B	↑ 8.96%
Net Profit Margin	36.68%	↓ 0.52%

	Q2 FY23	Q/Q Change
Revenue	$2.5B	↑ 4.99%
Net Income	$915.7M	↑ 30.85%
Net Profit Margin	36.73%	↑ 7.26%

	Q3 FY23	Q/Q Change
Revenue	$2.5B	↓ 0.39%
Net Income	$1.0B	↑ 13.06%
Net Profit Margin	41.69%	↑ 4.96%

	Q4 FY23	Q/Q Change
Revenue	$2.5B	↑ 1.38%
Net Income	$968.8M	↓ 6.42%
Net Profit Margin	38.48%	↓ 3.21%

	Q1 FY24	Q/Q Change
Revenue	$2.7B	↑ 6.73%
Net Income	$1.1B	↑ 13.5%
Net Profit Margin	40.92%	↑ 2.44%

	Q2 FY24	Q/Q Change
Revenue	$2.6B	↓ 1.95%
Net Income	$-3.6B	↓ 426.81%
Net Profit Margin	-136.4%	↓ 177.32%

	Q3 FY24	Q/Q Change
Revenue	$2.8B	↑ 5.21%
Net Income	$1.0B	↓ 129.09%
Net Profit Margin	37.71%	↑ 174.11%

	FY18	Y/Y Change
Profit	$2.6B	↑ 19.18%

	FY19	Y/Y Change
Profit	$3.6B	↑ 37.04%

	FY20	Y/Y Change
Profit	$5.5B	↑ 51.29%

	FY21	Y/Y Change
Profit	$6.7B	↑ 21.96%

	FY22	Y/Y Change
Profit	$7.9B	↑ 17.69%

	FY23	Y/Y Change
Profit	$8.6B	↑ 9.64%

	Q2 FY23	Q/Q Change
Profit	$2.2B	↑ 3.64%

	Q3 FY23	Q/Q Change
Profit	$2.2B	↓ 0.91%

	Q4 FY23	Q/Q Change
Profit	$2.1B	↓ 0.7%

	Q1 FY24	Q/Q Change
Profit	$2.3B	↑ 9.07%

	Q2 FY24	Q/Q Change
Profit	$2.3B	↓ 3.49%

	Q3 FY24	Q/Q Change
Profit	$2.4B	↑ 5.15%

	FY18	Y/Y Change
Operating Cash Flow	$1.3B	↑ 50.34%
Investing Cash Flow	$-202.2M	↓ 53.81%
Financing Cash Flow	$-71.2M	↓ 204.12%

	FY19	Y/Y Change
Operating Cash Flow	$1.6B	↑ 23.54%
Investing Cash Flow	$-1.2B	↑ 511.07%
Financing Cash Flow	$126.8M	↓ 278.0%

	FY20	Y/Y Change
Operating Cash Flow	$3.3B	↑ 107.32%
Investing Cash Flow	$99.4M	↓ 108.05%
Financing Cash Flow	$-505.3M	↓ 498.57%

	FY21	Y/Y Change
Operating Cash Flow	$2.6B	↓ 18.75%
Investing Cash Flow	$-340.9M	↓ 443.0%
Financing Cash Flow	$-1.5B	↑ 192.51%

	FY22	Y/Y Change
Operating Cash Flow	$4.1B	↑ 56.23%
Investing Cash Flow	$-321.1M	↓ 5.81%
Financing Cash Flow	$-67.7M	↓ 95.42%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$1.1B	↑ 26.06%
Investing Cash Flow	$-303.9M	↓ 83.43%
Financing Cash Flow	$17.3M	↓ 105.87%

Vertex Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Vertex Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Vertex Pharmaceuticals Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Vertex Pharmaceuticals Incorporated	-12.22%	-14.5%	-0.59%	82.27%	83.4%
Regeneron Pharmaceuticals, Inc.	-4.59%	-33.11%	-15.82%	12.66%	91.56%
Biontech Se	-6.0%	37.55%	8.38%	-55.46%	248.4%
Alnylam Pharmaceuticals, Inc.	-3.47%	-1.19%	26.71%	50.37%	106.11%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Vertex Pharmaceuticals Incorporated	32.84	NA	1.04	0.54	-0.03	0.12	NA	60.65
Regeneron Pharmaceuticals, Inc.	17.36	17.36	1.04	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Vertex Pharmaceuticals Incorporated	Buy	$102.3B	83.4%	32.84	-4.51%
Regeneron Pharmaceuticals, Inc.	Buy	$77.1B	91.56%	17.36	33.61%
Biontech Se	Buy	$27.1B	248.4%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$31.7B	106.11%	NA	-15.86%

About Vertex Pharmaceuticals

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.

Organization	Vertex Pharmaceuticals
Employees	5400
CEO	Dr. Jeffrey Marc Leiden M.D., Ph.D.
Industry	Health Technology

Management People of Vertex Pharmaceuticals

Name	Title
Dr. Jeffrey Marc Leiden M.D., Ph.D.	Executive Chairman
Dr. Reshma Kewalramani FASN, M.D.	CEO, President & Director
Mr. Charles F. Wagner Jr.	Executive VP & CFO
Mr. Stuart A. Arbuckle B.Sc.	Executive VP & COO
Dr. David M. Altshuler M.D., Ph.D.	Executive VP & Chief Scientific Officer
Ms. Kristen C. Ambrose CPA	Senior VP & Chief Accounting Officer
Mr. Mike Tirozzi	SVP and Chief Information & Data Officer
Ms. Susie Lisa C.F.A.	Senior Vice President of Investor Relations
Mr. Jonathan Biller J.D.	Executive VP & Chief Legal Officer
Ms. Nina Devlin	Senior VP & Chief Communications Officer

Important FAQs about investing in Vertex Pharmaceuticals from India :

What is Vertex Pharmaceuticals share price today?

Vertex Pharmaceuticals share price today stands at $407.20, Open: $401.53 ; Previous Close: $405.27 ; High: $410.68 ; Low: $402.32 ; 52 Week High: $519.88 ; 52 Week Low: $377.85. The stock opens at $401.53, after a previous close of $405.27. The stock reached a daily high of $410.68 and a low of $402.32, with a 52-week high of $519.88 and a 52-week low of $377.85.

Can Indians buy Vertex Pharmaceuticals shares?

Yes, Indians can invest in the Vertex Pharmaceuticals (VRTX) from India.

With INDmoney, you can buy Vertex Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Vertex Pharmaceuticals at zero transaction cost.

How can I buy Vertex Pharmaceuticals shares from India?

It is very easy to buy Vertex Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Vertex Pharmaceuticals be purchased?

Yes, you can buy fractional shares of Vertex Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Vertex Pharmaceuticals stocks?

To start investing in Vertex Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.